Dr. Dawei Li 李大卫
Chief Physician, Associate Professor
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive surgery for gastrointestinal tumors, including laparoscopic radical gastrectomy and sphincter-preserving surgery for low rectal cancer. Also treats rare malignancies and advanced recurrent or metastatic gastrointestinal tumors.
Dr. Li is a Chief Physician and doctoral supervisor at Fudan University Shanghai Cancer Center. Dr. Li earned a joint MD-PhD in Surgery from Shanghai Jiao Tong University School of Medicine and M.D. Anderson Cancer Center. Clinical focus includes minimally invasive and comprehensive treatment of gastrointestinal tumors, with expertise in complex recurrent or multiple primary malignancies.
Professional roles
- Member and Secretary, Abdominal Tumor Comprehensive Treatment Group, Anorectal Physicians Branch, Chinese Medical Doctor Association
- Member, Pelvic Tumor Surgery Expert Group, Surgical Physicians Branch, Chinese Medical Doctor Association
- Secretary, Neuroendocrine Tumor Committee, China Anti-Cancer Association
- Member, American Society of Clinical Oncology
Name order: in Chinese the family name comes first (Li Dawei). Papers usually list the name as Dawei Li or Li D.
Selected publications
56 papers on PubMed matched by name and affiliation; 16 as first or senior author since 2016. Most recent first- or senior-author papers:
- Nat Commun, 2026 (senior author): Inhibition of circulating glycocholic acid-regulated signaling potentiates immune checkpoint therapy in colorectal cancer. PubMed 41935049
- Phytomedicine, 2025 (senior author): Huaier overcomes tumor-induced immunosuppression in colorectal cancer by activating MHC I and CD8+ T cells. PubMed 40876126
- Cell Death Dis, 2024 (senior author): HIF1A-AS2 promotes the metabolic reprogramming and progression of colorectal cancer via miR-141-3p/FOXC1 axis. PubMed 39227375
- J Exp Clin Cancer Res, 2023 (senior author): Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches. PubMed 37480104
- Int J Biol Sci, 2023 (senior author): BST2 induced macrophage M2 polarization to promote the progression of colorectal cancer. PubMed 36594082
- Cancer Med, 2023 (senior author): Construction of a prognostic glycolysis-related lncRNA signature for patients with colorectal cancer. PubMed 35616307
- J Hematol Oncol, 2022 (senior author): Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications. PubMed 36319992
- J Immunol Res, 2022 (senior author): A Hypoxia-Related lncRNA Signature Correlates with Survival and Tumor Microenvironment in Colorectal Cancer. PubMed 35846431
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion